- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model NEW YORK ( TheStreet) -- Biogen Idec (Nasdaq: BIIB) hit a new 52-week high Thursday as it is currently trading at $151.03, above its previous 52-week high of $150.29 with 282,151 shares traded as of 10 a.m. ET. Average volume has been 981,100 shares over the past 30 days. Biogen Idec has a market cap of $34.76 billion and is part of the health care sector and drugs industry. Shares are up 33.6% year to date as of the close of trading on Wednesday. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 26.6, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.